1
|
Aayush A, Darji S, Estes KM, Yeh E, Thompson DH. Development of an Elastin-like Polypeptide-Based Nucleic Acid Delivery System Targeted to EGFR+ Bladder Cancer Cells Using a Layer-by-Layer Approach. Biomacromolecules 2024; 25:5729-5744. [PMID: 39185801 PMCID: PMC11388462 DOI: 10.1021/acs.biomac.4c00165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/27/2024]
Abstract
Nucleic acid (NA)-based therapies are revolutionizing biomedical research through their ability to control cellular functions at the genetic level. This work demonstrates a versatile elastin-like polypeptide (ELP) carrier system using a layer-by-layer (LbL) formulation approach that delivers NA cargos ranging in size from siRNA to plasmids. The components of the system can be reconfigured to modulate the biochemical and biophysical characteristics of the carrier for engaging the unique features of the biological target. We show the physical characterization and biological performance of LbL ELP nucleic acid nanoparticles (LENNs) in murine and human bladder tumor cell lines. Targeting bladder tumors is difficult owing to the constant influx of urine into the bladder, leading to low contact times (typically <2 h) for therapeutic agents delivered via intravesical instillation. LENN complexes bind to bladder tumor cells within 30 min and become rapidly internalized to release their NA cargo within 60 min. Our data show that a readily adaptable NA-delivery system has been created that is flexible in its targeting ability, cargo size, and disassembly kinetics. This approach provides an alternative path to either lipid nanoparticle formulations that suffer from inefficiency and physicochemical instability or viral vectors that are plagued by manufacturing and immune rejection challenges. This agile ELP-based nanocarrier provides an alternative route for nucleic acid delivery using a biomanufacturable, biodegradable, biocompatible, and highly tunable vehicle capable of targeting cells via engagement with overexpressed cell surface receptors.
Collapse
Affiliation(s)
- Aayush Aayush
- Department of Chemistry & Purdue Institute for Cancer Research, Purdue University, Bindley Bioscience Center, West Lafayette, Indiana 47907, United States
| | - Saloni Darji
- Department of Chemistry & Purdue Institute for Cancer Research, Purdue University, Bindley Bioscience Center, West Lafayette, Indiana 47907, United States
| | - Kiera M Estes
- Department of Chemistry & Purdue Institute for Cancer Research, Purdue University, Bindley Bioscience Center, West Lafayette, Indiana 47907, United States
| | - Emily Yeh
- Department of Chemistry & Purdue Institute for Cancer Research, Purdue University, Bindley Bioscience Center, West Lafayette, Indiana 47907, United States
| | - David H Thompson
- Department of Chemistry & Purdue Institute for Cancer Research, Purdue University, Bindley Bioscience Center, West Lafayette, Indiana 47907, United States
| |
Collapse
|
2
|
Mycobacterial Adhesion: From Hydrophobic to Receptor-Ligand Interactions. Microorganisms 2022; 10:microorganisms10020454. [PMID: 35208908 PMCID: PMC8875947 DOI: 10.3390/microorganisms10020454] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 02/07/2022] [Accepted: 02/12/2022] [Indexed: 11/24/2022] Open
Abstract
Adhesion is crucial for the infective lifestyles of bacterial pathogens. Adhesion to non-living surfaces, other microbial cells, and components of the biofilm extracellular matrix are crucial for biofilm formation and integrity, plus adherence to host factors constitutes a first step leading to an infection. Adhesion is, therefore, at the core of pathogens’ ability to contaminate, transmit, establish residency within a host, and cause an infection. Several mycobacterial species cause diseases in humans and animals with diverse clinical manifestations. Mycobacterium tuberculosis, which enters through the respiratory tract, first adheres to alveolar macrophages and epithelial cells leading up to transmigration across the alveolar epithelium and containment within granulomas. Later, when dissemination occurs, the bacilli need to adhere to extracellular matrix components to infect extrapulmonary sites. Mycobacteria causing zoonotic infections and emerging nontuberculous mycobacterial pathogens follow divergent routes of infection that probably require adapted adhesion mechanisms. New evidence also points to the occurrence of mycobacterial biofilms during infection, emphasizing a need to better understand the adhesive factors required for their formation. Herein, we review the literature on tuberculous and nontuberculous mycobacterial adhesion to living and non-living surfaces, to themselves, to host cells, and to components of the extracellular matrix.
Collapse
|
3
|
Samaddar S, Mazur J, Sargent J, Thompson DH. Immunostimulatory Response of RWFV Peptide-Targeted Lipid Nanoparticles on Bladder Tumor Associated Cells. ACS APPLIED BIO MATERIALS 2021; 4:3178-3188. [PMID: 35014405 DOI: 10.1021/acsabm.0c01572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Bladder carcinoma is the most expensive tumor type to treat on a cost-per-patient basis from diagnosis to death. Treatment with Bacillus Calmette Guerin (BCG) instillation is the only approved immunotherapy in the clinic for the remission of superficial bladder carcinoma. Unfortunately, frequent relapses, high local morbidity, risk of systemic mycobacterial infection, and occasional supply chain interruptions limit the utility of BCG for bladder cancer treatment. It is well known that BCG utilizes an adhesin protein known as fibronectin attachment protein that possesses a crucial RWFV peptide sequence for binding to the bladder tumor microenvironment prior to the initiation of the immunotherapeutic response. We report a RWFV-targeted, pH-responsive stabilized lipid nucleic acid nanoparticle (LNP) vehicle for the effective delivery of an immunotherapeutic oligonucleotide, CpG, that is assembled using a glass microfluidic Chemtrix 3221 reactor. Our small-angle X-ray scattering studies revealed a layer-by-layer assembly of the oligonucleotides with a repeat distance of 6.04 nm within the LNP. Using flow cytometry to evaluate the different cell types found in the bladder tumor microenvironment, RWFV-targeted LNPs were found to attach specifically to fibronectin-secreting cells in culture during a 2 h incubation period. The trafficking and cellular fate of these targeted LNPs were revealed by confocal microscopy of RAW264.7 macrophages to enter the endocytotic pathway within 4 h post treatment. Importantly, control studies reveal that only the pH-sensitive LNP formulation is capable of efficiently releasing the payload within 12 h. As a result, the targeted pH-sensitive LNP resulted in higher expression levels of costimulatory molecules CD83, CD 86, and MHC II, while also inducing higher levels of TNF-α secretion from macrophages. These results demonstrate that RWFV-targeted, pH-sensitive LNP formulations are capable of maximum immunotherapeutic response, potentially making them a highly efficient, lower risk, and readily manufactured alternative to BCG immunotherapy.
Collapse
Affiliation(s)
- Shayak Samaddar
- Multi-disciplinary Cancer Research Facility, Bindley Bioscience Center, Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States
| | - Joshua Mazur
- Multi-disciplinary Cancer Research Facility, Bindley Bioscience Center, Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States
| | - Jessica Sargent
- Multi-disciplinary Cancer Research Facility, Bindley Bioscience Center, Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States
| | - David H Thompson
- Multi-disciplinary Cancer Research Facility, Bindley Bioscience Center, Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States
| |
Collapse
|
4
|
Rius-Rocabert S, Llinares Pinel F, Pozuelo MJ, García A, Nistal-Villan E. Oncolytic bacteria: past, present and future. FEMS Microbiol Lett 2020; 366:5521890. [PMID: 31226708 DOI: 10.1093/femsle/fnz136] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2019] [Accepted: 06/18/2019] [Indexed: 02/06/2023] Open
Abstract
More than a century ago, independent groups raised the possibility of using bacteria to selectively infect tumours. Such treatment induces an immune reaction that can cause tumour rejection and protect the patient against further recurrences. One of the first holistic approximations to use bacteria in cancer treatment was performed by William Coley, considered the father of immune-therapy, at the end of XIX century. Since then, many groups have used different bacteria to test their antitumour activity in animal models and patients. The basis for this reactivity implies that innate immune responses activated upon bacteria recognition, also react against the tumour. Different publications have addressed several aspects of oncolytic bacteria. In the present review, we will focus on revisiting the historical aspects using bacteria as oncolytic agents and how they led to the current clinical trials. In addition, we address the molecules present in oncolytic bacteria that induce specific toxic effects against the tumors as well as the activation of host immune responses in order to trigger antitumour immunity. Finally, we discuss future perspectives that could be considered in the different fields implicated in the implementation of this kind of therapy in order to improve the current use of bacteria as oncolytic agents.
Collapse
Affiliation(s)
- Sergio Rius-Rocabert
- Microbiology Section, Pharmaceutical and Health Science Department. Faculty of Pharmacy. Instituto de Medicina Molecular Aplicada (IMMA). San Pablo-CEU University. CEU Universities, Campus Montepríncipe. Boadilla del Monte, E-28668 Madrid, Spain
| | - Francisco Llinares Pinel
- Microbiology Section, Pharmaceutical and Health Science Department. Faculty of Pharmacy. Instituto de Medicina Molecular Aplicada (IMMA). San Pablo-CEU University. CEU Universities, Campus Montepríncipe. Boadilla del Monte, E-28668 Madrid, Spain
| | - Maria Jose Pozuelo
- Microbiology Section, Pharmaceutical and Health Science Department. Faculty of Pharmacy. Instituto de Medicina Molecular Aplicada (IMMA). San Pablo-CEU University. CEU Universities, Campus Montepríncipe. Boadilla del Monte, E-28668 Madrid, Spain
| | - Antonia García
- Centre for Metabolomics and Bioanalysis (CEMBIO), Chemistry and Biochemistry Department, Faculty of Pharmacy, San Pablo-CEU University, Boadilla del Monte, E-28668 Madrid, Spain
| | - Estanislao Nistal-Villan
- Microbiology Section, Pharmaceutical and Health Science Department. Faculty of Pharmacy. Instituto de Medicina Molecular Aplicada (IMMA). San Pablo-CEU University. CEU Universities, Campus Montepríncipe. Boadilla del Monte, E-28668 Madrid, Spain
| |
Collapse
|
5
|
Samaddar S, Mazur J, Boehm D, Thompson DH. Development And In Vitro Characterization Of Bladder Tumor Cell Targeted Lipid-Coated Polyplex For Dual Delivery Of Plasmids And Small Molecules. Int J Nanomedicine 2019; 14:9547-9561. [PMID: 31824150 PMCID: PMC6900316 DOI: 10.2147/ijn.s225172] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Accepted: 10/22/2019] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND Bladder cancer is the fourth most common cancer in men and eleventh most common in women. Combination therapy using a gene and chemotherapeutic drug is a potentially useful strategy for treating bladder cancer in cases where a synergistic benefit can be achieved successfully. This approach relies on developing drug combinations using carrier systems that can load both hydrophilic genes and hydrophobic drugs. Ideally, the formulation for carrier system should be free of traditional high shear techniques such as sonication and extrusion to reduce shear-induced nucleic acid strand breakage. Moreover, the system should be able to protect the nucleic acid from enzymatic attack and deliver it specifically to the tumor site. MATERIALS AND METHODS A dual payload carrier system that was formulated using a simple flow mixing technique to complex anionic plasmid (EGFP-NLS) using a cationic polymer (CD-PEI2.5kD) followed by coating of the polyplex using lipid membranes. The resulting lipid-coated polyplex (LCP) formulations are targeted to bladder cancer cells by employing a bacterial adhesive peptide sequence, RWFV, that targets the LCP to the tumor stroma for efficiently delivering reporter plasmid, EGFP-NLS and a model small molecule drug, pyrene, to the cancer cells. RESULTS Encapsulation efficiency of the peptide targeted carrier for the plasmid was 50% ± 0.4% and for pyrene it was 16% ± 0.4%. The ability of the targeted LCP to transfect murine bladder cancer cells was 4-fold higher than LCP bearing a scrambled peptide sequence. Fluorescence of cells due to pyrene delivery was highest after 4 hrs using targeted LCP. Finally, we loaded the peptide targeted LCP with anti-cancer agent, curcumin. The targeted formulation of curcumin resulted in only 45% viable cancer cells at a concentration of 5 µg/mL, whereas the empty and non-targeted formulations did not result any significant cell death. CONCLUSION These results demonstrate the specificity of the targeting peptide sequence in engaging tumor cells and the utility of the developed carrier platform to deliver a dual payload to bladder tumor cells.
Collapse
Affiliation(s)
- Shayak Samaddar
- Department of Chemistry, Purdue University, Bindley Bioscience Center, West Lafayette, Indiana47906, USA
| | - Joshua Mazur
- Department of Chemistry, Purdue University, Bindley Bioscience Center, West Lafayette, Indiana47906, USA
| | - Devin Boehm
- Department of Chemistry, Purdue University, Bindley Bioscience Center, West Lafayette, Indiana47906, USA
| | - David H Thompson
- Department of Chemistry, Purdue University, Bindley Bioscience Center, West Lafayette, Indiana47906, USA
| |
Collapse
|
6
|
Jack S, Madhivanan K, Ramadesikan S, Subramanian S, Edwards DF, Elzey BD, Dhawan D, McCluskey A, Kischuk EM, Loftis AR, Truex N, Santos M, Lu M, Rabideau A, Pentelute B, Collier J, Kaimakliotis H, Koch M, Ratliff TL, Knapp DW, Aguilar RC. A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera. Int J Cancer 2019; 146:449-460. [PMID: 31584195 DOI: 10.1002/ijc.32719] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Revised: 08/10/2019] [Accepted: 09/11/2019] [Indexed: 12/20/2022]
Abstract
Bladder cancer is the sixth most common cancer in the United States, and it exhibits an alarming 70% recurrence rate. Thus, the development of more efficient antibladder cancer approaches is a high priority. Accordingly, this work provides the basis for a transformative anticancer strategy that takes advantage of the unique characteristics of the bladder. Unlike mucin-shielded normal bladder cells, cancer cells are exposed to the bladder lumen and overexpress EGFR. Therefore, we used an EGF-conjugated anthrax toxin that after targeting EGFR was internalized and triggered apoptosis in exposed bladder cancer cells. This unique agent presented advantages over other EGF-based technologies and other toxin-derivatives. In contrast to known agents, this EGF-toxin conjugate promoted its own uptake via receptor microclustering even in the presence of Her2 and induced cell death with a LC50 < 1 nM. Furthermore, our data showed that exposures as short as ≈3 min were enough to commit human (T24), mouse (MB49) and canine (primary) bladder cancer cells to apoptosis. Exposure of tumor-free mice and dogs with the agent resulted in no toxicity. In addition, the EGF-toxin was able to eliminate cells from human patient tumor samples. Importantly, the administration of EGF-toxin to dogs with spontaneous bladder cancer, who had failed or were not eligible for other therapies, resulted in ~30% average tumor reduction after one treatment cycle. Because of its in vitro and in vivo high efficiency, fast action (reducing treatment time from hours to minutes) and safety, we propose that this EGF-anthrax toxin conjugate provides the basis for new, transformative approaches against bladder cancer.
Collapse
Affiliation(s)
- Sherwin Jack
- Purdue University Center for Cancer Research, West Lafayette, IN.,Department of Biological Sciences, Purdue University, West Lafayette, IN
| | - Kayalvizhi Madhivanan
- Purdue University Center for Cancer Research, West Lafayette, IN.,Department of Biological Sciences, Purdue University, West Lafayette, IN
| | - Swetha Ramadesikan
- Purdue University Center for Cancer Research, West Lafayette, IN.,Department of Biological Sciences, Purdue University, West Lafayette, IN
| | - Sneha Subramanian
- Purdue University Center for Cancer Research, West Lafayette, IN.,Department of Biological Sciences, Purdue University, West Lafayette, IN
| | - Daniel F Edwards
- Purdue University Center for Cancer Research, West Lafayette, IN.,Department of Biological Sciences, Purdue University, West Lafayette, IN
| | - Bennett D Elzey
- Purdue University Center for Cancer Research, West Lafayette, IN.,Department of Comparative Pathobiology, Purdue University, West Lafayette, IN.,Department of Urology, Indiana University School of Medicine, Indianapolis, IN
| | - Deepika Dhawan
- Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN
| | | | - Erin M Kischuk
- Purdue University Center for Cancer Research, West Lafayette, IN.,Department of Comparative Pathobiology, Purdue University, West Lafayette, IN
| | - Alexander R Loftis
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA
| | - Nicholas Truex
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA
| | - Michael Santos
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA
| | - Mike Lu
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA
| | - Amy Rabideau
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA
| | - Bradley Pentelute
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA.,Koch Institute MIT, Cambridge, MA.,Broad Institute of Harvard and MIT, Cambridge, MA.,Center for Environmental Health Sciences MIT, Cambridge, MA
| | - John Collier
- Department of Microbiology, Harvard Medical School, Boston, MA
| | | | - Michael Koch
- Department of Urology, Indiana University School of Medicine, Indianapolis, IN
| | - Timothy L Ratliff
- Purdue University Center for Cancer Research, West Lafayette, IN.,Department of Comparative Pathobiology, Purdue University, West Lafayette, IN
| | - Deborah W Knapp
- Purdue University Center for Cancer Research, West Lafayette, IN.,Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN
| | - Ruben C Aguilar
- Purdue University Center for Cancer Research, West Lafayette, IN.,Department of Biological Sciences, Purdue University, West Lafayette, IN
| |
Collapse
|
7
|
Yoshino T, Miyazaki J, Kojima T, Kandori S, Shiga M, Kawahara T, Kimura T, Naka T, Kiyohara H, Watanabe M, Yamasaki S, Akaza H, Yano I, Nishiyama H. Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model. PLoS One 2019; 14:e0209196. [PMID: 30608942 PMCID: PMC6319727 DOI: 10.1371/journal.pone.0209196] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2018] [Accepted: 11/30/2018] [Indexed: 01/18/2023] Open
Abstract
Intravesical therapy using Mycobacterium bovis bacillus Calmette-Guérin (BCG) is the most established cancer immunotherapy for bladder cancer. However, its underlying mechanisms are unknown. Mycolic acid (MA), the most abundant lipid of the BCG cell wall, is suspected to be one of the essential active components of this immunogenicity. Here, we developed cationic liposomes incorporating three subclasses (α, keto, and methoxy) of MA purified separately from BCG, using the dendron-bearing lipid D22. The cationic liposomes using D22 were efficiently taken up by the murine bladder cancer cell line MB49 in vitro, but the non-cationic liposomes were not. Lip-kMA, a cationic liposome containing keto-MA, presented strong antitumor activity in two murine syngeneic graft models using the murine bladder cancer cell lines MB49 and MBT-2 in comparison to both Lip-aMA and Lip-mMA, which contained α-MA and methoxy-MA, respectively. Interestingly, Lip-kMA(D12), which was made of D12 instead of D22, did not exhibit antitumor activity in the murine syngeneic graft model using MB49 cells, although it was successfully taken up by MB49 cells in vitro. Histologically, compared to the number of infiltrating CD4 lymphocytes, the number of CD8 lymphocytes was higher in the tumors treated with Lip-kMA. Antitumor effects of Lip-kMA were not observed in nude mice, whereas weak but significant effects were observed in beige mice with natural killer activity deficiency. Thus, a cationized liposome containing keto-MA derived from BCG induced in vivo antitumor immunity. These findings will provide new insights into lipid immunogenicity and the underlying mechanisms of BCG immunotherapy.
Collapse
Affiliation(s)
- Takayuki Yoshino
- Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - Jun Miyazaki
- Department of Urology, International University of Health and Welfare, Chiba, Japan
- * E-mail:
| | - Takahiro Kojima
- Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - Shuya Kandori
- Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - Masanobu Shiga
- Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - Takashi Kawahara
- Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - Tomokazu Kimura
- Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - Takashi Naka
- Department of Food and Nutrition, Faculty of Contemporary Human Life Science, Tezukayama University, Nara, Japan
| | | | - Miyuki Watanabe
- Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
- Division of Molecular Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
| | - Sho Yamasaki
- Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
- Division of Molecular Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
- Department of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan
- Division of Molecular Immunology, Medical Mycology Research Center, Chiba University, Chiba, Japan
| | - Hideyuki Akaza
- Strategic Investigation on Comprehensive Cancer Network, University of Tokyo, Tokyo, Japan
| | | | - Hiroyuki Nishiyama
- Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| |
Collapse
|
8
|
Lee Y, Kischuk E, Crist S, Ratliff TL, Thompson DH. Targeting and Internalization of Liposomes by Bladder Tumor Cells Using a Fibronectin Attachment Protein-Derived Peptide-Lipopolymer Conjugate. Bioconjug Chem 2017; 28:1481-1490. [PMID: 28475311 DOI: 10.1021/acs.bioconjchem.7b00153] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
A synthetic peptidolipopolymer conjugate, incorporated into liposomes to promote specific binding to the fibronectin (FBN) matrix surrounding bladder tumor cells and promote cellular internalization of FBN-integrin complexes, is reported. The peptide promotes association with MB49 mouse model bladder tumor cells in a sequence-specific and concentration-dependent manner, with the maximum cell association occurring at 2 mol % RWFV-PEG2000-DSPE. Double PEGylation of the liposome membrane (i.e., 4 mol % mPEG1000-DSPE + 2 mol % RWFV-PEG2000-DSPE) enhanced binding by >1.6-fold, by improving ligand presentation on the liposome surface. The sequence specificity of the peptide-lipopolymer construct was confirmed by comparing liposomes containing RWFV-PEG2000-DSPE with scrambled and nonpeptidic lipopolymer liposomal formulations. MB49 tumor-bearing mice showed greater mean radiance values for FAP peptide-targeted liposomes in tumor-associated regions of interest than for nontargeted and scrambled peptide liposome formulations. These findings suggest that peptide-modified liposomes may be an attractive vehicle for targeted delivery to bladder tumors in vivo.
Collapse
Affiliation(s)
- Young Lee
- Purdue University Center for Cancer Research, Multi-disciplinary Cancer Research Facility, Purdue University , 1203 West State Street, West Lafayette, Indiana 47907, United States
| | - Erin Kischuk
- Purdue University Center for Cancer Research, Multi-disciplinary Cancer Research Facility, Purdue University , 1203 West State Street, West Lafayette, Indiana 47907, United States
| | - Scott Crist
- Purdue University Center for Cancer Research, Multi-disciplinary Cancer Research Facility, Purdue University , 1203 West State Street, West Lafayette, Indiana 47907, United States
| | - Timothy L Ratliff
- Purdue University Center for Cancer Research, Multi-disciplinary Cancer Research Facility, Purdue University , 1203 West State Street, West Lafayette, Indiana 47907, United States
| | - David H Thompson
- Purdue University Center for Cancer Research, Multi-disciplinary Cancer Research Facility, Purdue University , 1203 West State Street, West Lafayette, Indiana 47907, United States
| |
Collapse
|
9
|
Noguera-Ortega E, Blanco-Cabra N, Rabanal RM, Sánchez-Chardi A, Roldán M, Guallar-Garrido S, Torrents E, Luquin M, Julián E. Mycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment. Sci Rep 2016; 6:27232. [PMID: 27265565 PMCID: PMC4893706 DOI: 10.1038/srep27232] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2015] [Accepted: 05/17/2016] [Indexed: 12/22/2022] Open
Abstract
The hydrophobic composition of mycobacterial cell walls leads to the formation of clumps when attempting to resuspend mycobacteria in aqueous solutions. Such aggregation may interfere in the mycobacteria-host cells interaction and, consequently, influence their antitumor effect. To improve the immunotherapeutic activity of Mycobacterium brumae, we designed different emulsions and demonstrated their efficacy. The best formulation was initially selected based on homogeneity and stability. Both olive oil (OO)- and mineral oil-in-water emulsions better preserved the mycobacteria viability and provided higher disaggregation rates compared to the others. But, among both emulsions, the OO emulsion increased the mycobacteria capacity to induce cytokines’ production in bladder tumor cell cultures. The OO-mycobacteria emulsion properties: less hydrophobic, lower pH, more neutralized zeta potential, and increased affinity to fibronectin than non-emulsified mycobacteria, indicated favorable conditions for reaching the bladder epithelium in vivo. Finally, intravesical OO-M. brumae-treated mice showed a significantly higher systemic immune response, together with a trend toward increased tumor-bearing mouse survival rates compared to the rest of the treated mice. The physicochemical characteristics and the induction of a robust immune response in vitro and in vivo highlight the potential of the OO emulsion as a good delivery vehicle for the mycobacterial treatment of bladder cancer.
Collapse
Affiliation(s)
- Estela Noguera-Ortega
- Departament de Genètica i de Microbiologia, Facultat de Biociències, Universitat Autònoma de Barcelona, Spain
| | - Núria Blanco-Cabra
- Departament de Genètica i de Microbiologia, Facultat de Biociències, Universitat Autònoma de Barcelona, Spain
| | - Rosa Maria Rabanal
- Unitat de Patologia Murina i Comparada, Departament de Medicina i Cirurgia Animals, Facultat de Veterinària, Universitat Autònoma de Barcelona, Spain
| | | | - Mónica Roldán
- Servei de Microscopia, Universitat Autònoma de Barcelona, Spain
| | - Sandra Guallar-Garrido
- Departament de Genètica i de Microbiologia, Facultat de Biociències, Universitat Autònoma de Barcelona, Spain
| | - Eduard Torrents
- Bacterial Infections and Antimicrobial Therapy group, Institute for Bioengineering of Catalonia (IBEC), Spain
| | - Marina Luquin
- Departament de Genètica i de Microbiologia, Facultat de Biociències, Universitat Autònoma de Barcelona, Spain
| | - Esther Julián
- Departament de Genètica i de Microbiologia, Facultat de Biociències, Universitat Autònoma de Barcelona, Spain
| |
Collapse
|
10
|
Nakamura T, Fukiage M, Suzuki Y, Yano I, Miyazaki J, Nishiyama H, Akaza H, Harashima H. Mechanism responsible for the antitumor effect of BCG-CWS using the LEEL method in a mouse bladder cancer model. J Control Release 2014; 196:161-7. [PMID: 25315488 DOI: 10.1016/j.jconrel.2014.10.007] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2014] [Revised: 09/26/2014] [Accepted: 10/06/2014] [Indexed: 10/24/2022]
Abstract
We previously reported on the development of a water soluble formulation of the cell wall skeleton of BCG (BCG-CWS), a major immune active center of BCG, by encapsulating it into a nanoparticle (CWS-NP). The CWS-NP allowed us to clarify the machinery associated with the BCG mediated anti-bladder tumor effect, especially the roles of bladder cancer cells and dendritic cells (DCs) in the initial step, which remains poorly understood. We show herein that the internalization of BCG-CWS by bladder cancer cells, but not DCs, is indispensable for the induction of an antitumor effect against bladder cancer. Tumor growth was significantly inhibited in mice that had been inoculated with mouse bladder cancer (MBT-2) cells containing internalized BCG-CWS. On the other hand, the internalization of BCG-CWS by DCs had only a minor effect on inducing an antitumor effect against MBT-2 tumors. This was clarified for the first time by using the CWS-NP. This finding provides insights into our understanding of the role of bladder cancer cells and DCs in BCG therapy against bladder cancer.
Collapse
Affiliation(s)
- Takashi Nakamura
- Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
| | - Masafumi Fukiage
- Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
| | - Yoshiteru Suzuki
- Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
| | - Ikuya Yano
- Japan BCG Central Laboratory, Kiyose, Japan
| | - Jun Miyazaki
- Department of Urology, Faculty of Medicine, Tsukuba University, Tsukuba, Japan
| | - Hiroyuki Nishiyama
- Department of Urology, Faculty of Medicine, Tsukuba University, Tsukuba, Japan
| | - Hideyuki Akaza
- The University of Tokyo, Research Center for Advanced Science and Technology, Tokyo, Japan
| | | |
Collapse
|
11
|
Glycan-targeted drug delivery for intravesical therapy: in the footsteps of uropathogenic bacteria. Ther Deliv 2014; 5:537-53. [DOI: 10.4155/tde.14.25] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
The human urothelium belongs to the most efficient biobarriers, and represents a highly rewarding but challenging target for local drug administration. Inadequate urothelial bioavailability is a major obstacle for successful treatment of bladder cancer and other diseases, yet little research has addressed the development of advanced delivery concepts for the intravesical route. A prominent example of how to overcome the urothelial barrier by means of specific biorecognition is the efficient cytoinvasion of UPEC bacteria, mediated by the mannose-targeted lectin domain FimH. Similar mechanisms of non-bacterial origin may be exploited for enhancing drug uptake from the bladder cavity. This review covers the current status in the development of lectin-based delivery strategies for the urinary tract. Different concepts for preparing and optimizing carbohydrate-targeted delivery systems are presented, along with important design parameters, benefits and shortcomings. Bioconjugate- and nano-/microparticle-based systems are discussed in further detail with regard to their performance in preclinical testing.
Collapse
|
12
|
Nakamura T, Fukiage M, Higuchi M, Nakaya A, Yano I, Miyazaki J, Nishiyama H, Akaza H, Ito T, Hosokawa H, Nakayama T, Harashima H. Nanoparticulation of BCG-CWS for application to bladder cancer therapy. J Control Release 2014; 176:44-53. [DOI: 10.1016/j.jconrel.2013.12.027] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2013] [Revised: 12/20/2013] [Accepted: 12/21/2013] [Indexed: 11/17/2022]
|
13
|
Neutsch L, Eggenreich B, Herwig E, Marchetti-Deschmann M, Allmaier G, Gabor F, Wirth M. Biomimetic Delivery Strategies at the Urothelium: Targeted Cytoinvasion in Bladder Cancer Cells via Lectin Bioconjugates. Pharm Res 2013; 31:819-32. [DOI: 10.1007/s11095-013-1204-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2013] [Accepted: 09/12/2013] [Indexed: 10/25/2022]
|
14
|
Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. J Control Release 2013; 172:1020-34. [PMID: 24140748 DOI: 10.1016/j.jconrel.2013.10.012] [Citation(s) in RCA: 169] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2013] [Revised: 10/08/2013] [Accepted: 10/09/2013] [Indexed: 01/20/2023]
Abstract
Nanoparticles (NPs) have been extensively investigated for applications in both experimental and clinical settings to improve delivery efficiency of therapeutic and diagnostic agents. Most recently, novel multifunctional nanoparticles have attracted much attention because of their ability to carry diverse functionalities to achieve effective synergistic therapeutic treatments. Multifunctional NPs have been designed to co-deliver multiple components, target the delivery of drugs by surface functionalization, and realize therapy and diagnosis simultaneously. In this review, various materials of diverse chemistries for fabricating multifunctional NPs with distinctive architectures are discussed and compared. Recent progress involving multifunctional NPs for immune activation, anticancer drug delivery, and synergistic theranostics is the focus of this review. Overall, this comprehensive review demonstrates that multifunctional NPs have distinctive properties that make them highly suitable for targeted therapeutic delivery in these areas.
Collapse
|